Carisma Therapeutics, Inc. CARM
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -99.07%
- 1 year
- -99.20%
- Market cap
- 16.74K
- Revenue (ttm)
- 20.27M
- EPS (ttm)
- 0.19
- Shares out
- 41.75M
- P/E ratio
- 0.00
- Forward P/E
- -0.43
- YTD return
- -99.07%
- 1-year return
- -99.20%
- Volume
- 10.30K
- Avg volume
- 32.13K
- Open
- 0.02725
- Previous close
- 0.0002
- Day's range
- 0.0263 – 0.0324
- 52-week range
- 0.0001 – 0.10
- Analysts
- Hold
- Price target
- 4.57 (+1141567.5%)
2Y -1.0996 (-99.96%)
Key statistics
- Enterprise value
- -7.36M
- PEG ratio
- 0.00
- Price / sales
- 0.80
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -11.60%
- Free cash flow
- -41.39M
- Total cash
- 28.13M
- Total debt
- 3.32M
- Return on equity
- -362.79%
- Short % of float
- 1.66%
- 50-day average
- 0.85396
- 200-day average
- 1.25
Analyst view
Consensus: hold
- Target (low)
- 0.70
- Target (mean)
- 4.57
- Target (high)
- 12.00
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.19.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.31 | -0.31 | 0.00 | 0.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.36 | -0.27 | +0.09 | +25.00% |
| May 9, 2024 | Mar 1, 2024 | -0.37 | -0.46 | -0.09 | -24.32% |
| Apr 1, 2024 | Dec 1, 2023 | -0.56 | -0.52 | +0.04 | +7.14% |
| Nov 9, 2023 | Sep 1, 2023 | -0.60 | -0.53 | +0.07 | +11.67% |
| Aug 10, 2023 | Jun 1, 2023 | -0.66 | -0.49 | +0.17 | +25.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 12, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 12, 2024 | Baird | down | Outperform | Neutral |
| Dec 11, 2024 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 10, 2024 | BTIG | down | Buy | Neutral |
| Dec 9, 2024 | D. Boral Capital | main | Buy | Buy |
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- carismatx.com
News
Carmila: 2026 H1 Results 
Critical Review: Carisma Therapeutics (NASDAQ:CARM) vs. Protalex (OTCMKTS:PRTX) 
Carmila: 2025 Annual Results 
Financial Comparison: Context Therapeutics (NASDAQ:CNTX) vs. Carisma Therapeutics (NASDAQ:CARM) 
Carisma Announces Delisting from Nasdaq and SEC Deregistration 
Head-To-Head Survey: Achieve Life Sciences (NASDAQ:ACHV) vs. Carisma Therapeutics (NASDAQ:CARM) 
Carmanah Minerals Engages Warrior Drilling for Heritage Project; Targets Historic Eagle Zone on Burin Trend, NL 
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM) 
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on CARM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANNELL THOMAS R | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 1, 2023 | 672,386 |
| FORBES MONICA | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 1, 2023 | 505,664 |
| HODITS REGINA | Director | Stock Award(Grant) | Mar 6, 2023 | 0 |
| KLICHINSKY MICHAEL | Officer | Stock Award(Grant) | Mar 6, 2023 | 484,347 |
| MACDONALD GLEN C. | Chief Technology Officer | Conversion of Exercise of derivative security | Mar 1, 2023 | 398,918 |
| MORRISON BRIGGS W. M.D. | Director | Stock Award(Grant) | Mar 6, 2023 | 12,175 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.47% | 1,448,247 | 561.92K | Sep 29, 2024 |
| Trustees of the University of Pennsylvania | 3.00% | 1,252,107 | 485.82K | Sep 29, 2024 |
| TPG GP A, LLC | 1.34% | 561,442 | 217.84K | Sep 29, 2024 |
| Barclays Plc | 1.32% | 549,305 | 213.13K | Sep 29, 2024 |
| Blackrock Inc. | 0.98% | 408,564 | 158.52K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.62% | 259,184 | 100.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.53% | 1,054,783 | 409.25K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.82% | 342,628 | 132.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 132,874 | 51.55K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 61,238 | 23.76K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.11% | 47,703 | 18.51K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 40,366 | 15.66K | Oct 30, 2024 |